Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:5078565.
doi: 10.1155/2017/5078565. Epub 2017 Apr 9.

Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study

Qinrui Hu  1 , Yujing Bai  1 , Xiaoli Chen  1 , Lvzhen Huang  1 , Yi Chen  2 , Xiaoxin Li  1
Affiliations

Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study

Qinrui Hu et al. J Ophthalmol. 2017.

Abstract

Objective. To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment. Methods. This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases. Infants who developed Zone II Stage 3 ROP with plus disease and underwent initial intravitreal injection of ranibizumab (IVR) were recruited. Patients were divided into 2 groups based on the outcome after initial ranibizumab treatment: recurrence of ROP or favorable outcome. Data was collected and analyzed by SPSS 16.0. Results. Forty-two patients were included, and 80 eyes with Zone II Stage 3+ were subjected to IVR treatment. Eleven of 42 patients (26.2%, 18 eyes) had a recurrence of ROP after the initial treatment. On univariate analysis, preretinal hemorrhage before treatment was significantly different between the two groups (P = 0.000). Multivariate analysis found that preretinal hemorrhage before treatment was the only factor associated with the recurrence of ROP in our study (P = 0.004). Conclusions. The recurrence rate of ROP in Zone II Stage 3+ after initial ranibizumab treatment was notable and preretinal hemorrhage before treatment was associated with the recurrence of ROP in our study.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Results and secondary therapies of 80 eyes of infants with retinopathy of prematurity after initial ranibizumab treatment (IVR).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Martinez-Castellanos M. A., Schwartz S., Hernandez-Rojas M. L., et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina. 2013;33(2):329–338. doi: 10.1097/IAE.0b013e318275394a. - DOI - PubMed
    1. Romagnoli C. Risk factors and growth factors in ROP. Early Human Development. 2009;85(10 Supplement):S79–S82. doi: 10.1016/j.earlhumdev.2009.08.026. - DOI - PubMed
    1. Mutlu F. M., Sarici S. U. Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. International Journal of Ophthalmology. 2013;6(2):228–236. doi: 10.3980/j.issn.2222-3959.2013.02.23. - DOI - PMC - PubMed
    1. Chen S. N., Lian I., Hwang Y. C., et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina. 2015;35(4):667–674. doi: 10.1097/IAE.0000000000000380. - DOI - PubMed
    1. Kim M. J., Kim S. J., Yu Y. S. The risk for retinal detachment associated with hemorrhages pre- and postlaser treatment in retinopathy of prematurity. Retina. 2008;28(10):1451–1457. doi: 10.1097/IAE.0b013e31817f2f15. - DOI - PubMed